Grace Gorecki, MD

Internal Medicine PGY-3 @ AHN | Former UPMC Postdoctoral Fellow | Women’s cancer & immuno-oncology research 🔬🩷 | Aspiring Medical Oncologist 🧬 | 🇧🇷 🇺🇸

[Grace Gorecki, MD @grace_gorecki]

@TKapetanos @J_Hematology @AbioyeOyepejuMD @myelomadoctor @AHNhemeonc @AHNIMres Thank you, Dr. K! I’m only able to do this because of the amazing mentors who have guided and supported me throughout my journey and the opportunities our program has provided!

[Grace Gorecki, MD @grace_gorecki]

1/ Our new paper in @J_Hematology
couldn't have come at a better time: the ANDROMEDA final survival analysis just dropped, and our real-world data from 43,878 patients aligns perfectly 🎯
#ALAmyloidosis #ANDROMEDA #Daratumumab

[Oyepeju Abioye-Akintola, MD, MSc @AbioyeOyepejuMD]

🩸Read our latest publication in @J_Hematology evaluating evolving treatment options and survival trends (pre- & post- Daratumumab) in AL Amyloidosis over the last 2 decades.

🩸Link to article: https://t.co/Edu0XH1zDF

Congratulations @grace_gorecki!
@AHNIMres @AHNhemeonc

[Grace Gorecki, MD @grace_gorecki]

4/ Full paper 👉 https://t.co/XolStOJLtZ

#Amyloidosis #Hematology #RealWorldEvidence #ClinicalResearch

[Grace Gorecki, MD @grace_gorecki]

3/ 💊 In the daratumumab era (2021–2025 vs 2016–2020):
🔹 Stage I: 62% lower 1-yr mortality, median OS gain of 19 months
🔹 Stage IIIb: 51% lower 5-yr mortality
🔹 Dara-CyBorD vs CyBorD: HR 0.33 at 3 years (p<0.0001)

[Veli Bakalov, MD @HemeOncBuddy]

So proud to see AHN residents and fellows shine! @AHNhemeonc 💪

[AHN Hematology/Oncology Fellowship @AHNhemeonc]

Our fellows and residents had an incredible experience at #ASCO2026!🎉With outstanding mentorship from our faculty, we celebrated multiple accepted posters and a special ASCO Merit Award for our PGY-4 fellow, Dr Stanley Ozogbo. Congratulations to all!

[UPMC Heme-Onc Fellowship Program @UPMCHeme_Onc]

Shoutout to our own Dr. Randolph Lyde & Dr. Annie Im for leading this piece—along with Drs. Sean O’Neil & Lori Rosenstein—on what really matters when applying to HemOnc fellowship.

Mentorship, culture, and opportunity matter. Be intentional!

🔗 @ASH_hematology
#HemeOnc #MedEd

[Grace Gorecki, MD @grace_gorecki]

https://t.co/jEEY51hg9N

[Grace Gorecki, MD @grace_gorecki]

Excited to share our work at #ASCO2026!

We evaluated the prognostic value of ctDNA in epithelial ovarian cancer and found that ctDNA added significant prognostic value beyond CA-125 alone. (HR 3.48)

#OvarianCancer #GynOnc #ctDNA #CancerResearch #Oncology

[Grace Gorecki, MD @grace_gorecki]

Days like today make us excited for a world where there will be no such thing as an “undruggable” disease, as long as we continue to put in the work and advance research. The future is bright! 🔬 #ASCO26

[Mark Lewis, MD, FASCO @marklewismd]

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer

Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived

#ASCO26

[Oyepeju Abioye-Akintola, MD, MSc @AbioyeOyepejuMD]

Once again, at #ASCO26 I will be presenting research at the intersection of #GlobalOnc & #ClinicalTrials, this time on Clinical Trials reporting in African countries.

Come by Poster Board #507 for some fun learning this morning from 9am-12pm! @ascocancer

[Grace Gorecki, MD @grace_gorecki]

Beautiful and inspiring! Check out this piece from @AbioyeOyepejuMD

[Oyepeju Abioye-Akintola, MD, MSc @AbioyeOyepejuMD]

Bittersweet beginning of #ASCO26 for me, as I share the hardest, most precious narrative I’ve written.

Grateful to @OncJournal for housing this piece of my heart. For your tender readership:

Daddy is Dead: A Physician Reckons with Her Father's Mortality https://t.co/d88AaHT9TK

[Paolo Tarantino @PTarantinoMD]

Only few days to #ASCO26. For breast oncologists, this edition will deliver a new promising biomarker to spare unnecessary chemo, informative updates from practice-changing trials across subtypes, and major innovations coming from China. See you in Chicago next week! #bcsm

[Grace Gorecki, MD @grace_gorecki]

Have a real-world study supporting these findings coming out really soon!

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

1/ 🧵 ANDROMEDA final analysis is practice-changing for newly diagnosed AL amyloidosis.

IMPORTANT tweets: 3/4 and 6 for clinicians who treats Amyloidosis

D-VCd = daratumumab + bortezomib/cyclophosphamide/dexamethasone.

With 61.4 months median follow-up, D-VCd improved depth of response, organ recovery, MOD-PFS, and OS. 🔥
#USMIRC #MedEd #medtwitter #mmsm #myeloma @USMIRCNEWS @US_HMC @MedwatchKate @Larvol @OncoAlert

[MV Chandrakanth @ChandrakanthMv]

SATEEN Trial: ADC Sequencing Lesson
✅ Simple Breakdown:

• Who was studied?
Heavily pretreated HER2+ metastatic breast cancer patients who had already progressed on T-DXd (Enhertu). Median 5 prior lines, 33% had brain metastases.

• What was tested?
Switch from T-DXd to Sacituzumab Govitecan (Trodelvy) + trastuzumab.
→ Changed the target (HER2 → Trop-2)
→ But kept the same payload (TOPO1 inhibitor)

• What were the results?
ORR: 3.7%
mPFS: 2.3 months
→ Limited clinical activity. Trial stopped early.

• Key Takeaway
Changing the antibody target alone gives limited benefit if the payload stays the same.
To overcome resistance after T-DXd, future strategies should focus on changing the payload.
This is an important lesson for ADC sequencing in HER2+ breast cancer.

#SATEEN #ADCs #BreastCancer #HER2Positive #T-DXd #Trodelvy #Oncology #PrecisionMedicine #ESMOBreast2026 #MVOnco

[Prerna Mewawalla @myelomadoctor]

As the multiple myeloma treatment landscape continues to evolve, new targets beyond BCMA and GPRC5D are generating significant interest.

In this interview with @CancerNetwrk, I discuss the potential role of FcRH5-directed therapy with cevostamab and where it may fit into the future treatment paradigm for relapsed/refractory multiple myeloma.

Read more: https://t.co/8zTv96BquL #mmsm @oncodaily @MM_Hub